Acetylshikonin is effective in the treatment of obesity by suppressing the expression of adipogenic differentiation transcription factors and adipocyte-specific proteins, and by increasing the activity of cAMP-dependent protein kinase (PKA) and phosphorylation of hormone-sensitive lipase (HSL). This evidence concerns the gene LIPE and obesity disorder.